Research suggests that Shatavari, typically studied as part of polyherbal or multi-ingredient formulations rather than as a standalone ingredient, may play a role in supporting immune responses, though the evidence remains preliminary. Two small randomized controlled trials examined traditional Indian herbal combinations in the context of mild to moderate COVID-19, with one reporting statistically significant improvements in viral load reduction and Th1 immune response enhancement compared to placebo, while the other found no statistically significant differences between treatment and control groups on any measured outcome. Both studies involved small participant numbers, short durations, and multi-ingredient formulations, making it difficult to isolate the specific contribution of any single herb including Shatavari. Overall, the current body of evidence is too limited and methodologically constrained to draw firm conclusions about Shatavari's independent effects on immune function, and larger, well-designed trials are needed.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Efficacy and Safety of Polyherbal formulation as an add-on to the standard of... | Other | 2021 | — | 90 |
| AYUSH medicine as add-on therapy for mild category COVID-19; an open label ra... | Other | 2020 | — | 85 |